Protara Therapeutics Q2 net loss widens on higher expenses

Protara Therapeutics

11/08/2026 13:11

Overview
US biotech firm's Q2 net loss widened yr/yr as operating expenses increased
Company expects cash and investments to support operations into 2028
Clinical trial progress continues for TARA-002 and IV Choline Chloride, with milestones expected in 2026-2027

Outlook
Protara expects to complete enrollment of ADVANCED-2 BCG-Unresponsive cohort in 4Q 2026
Company expects to complete STARBORN-1 trial enrollment in LMs in 4Q 2026
Protara plans to submit BLA for TARA-002 in LMs in 2H 2027

Result Drivers
HIGHER R&D SPENDING - Co said increased research and development expenses were due to higher direct costs from ongoing clinical trials, increased personnel-related expenses, and manufacturing activities
CLINICAL TRIAL PROGRESS - Co highlighted continued enrollment and redesign of trials for TARA-002 and ongoing THRIVE-3 trial for IV Choline Chloride
INTERIM DATA PRESENTATION - Co presented updated interim safety and durability data from STARBORN-1 trial in LMs, supporting planned regulatory submission

Company press release: ID:nGNX4dXhHt

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.36
 
Q2 Net Loss
 
$21.67 mln
 
Q2 Income from Operations
 
-$23.32 mln
 
Q2 Operating Expenses
 
$23.32 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Protara Therapeutics Inc is $26.50, about 544.8% above its August 10 closing price of $4.11

Reuters Recommended Reads
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs
Aug 11 - Intensity Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)